Dorzolamide
A carbonic anhydrase inhibitor used as an eye drop to lower intraocular pressure in patients with glaucoma or ocular hypertension. It reduces fluid production inside the eye to help protect against vision loss.
Molekularmasse
324,4000 g/mol
LogP
0,40
TPSA
151,00 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Wirkmechanismus
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
2D-Struktur
Cite this structure
Embed this structure
SMILES
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21
InChI
InChI=1S/C10H16N2O4S3/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16)/t6-,8-/m0/s1
Molecular Formula
C10H16N2O4S3
HBD / HBA
2 / 7
Rotierbare Bindungen
3
Schwere Atome
19
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
A carbonic anhydrase inhibitor used as an eye drop to lower intraocular pressure in patients with glaucoma or ocular hypertension. It reduces fluid production inside the eye to help protect against vision loss.
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Yes, Dorzolamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL218490. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5284549. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="dorzolamide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/dorzolamide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/dorzolamide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/dorzolamide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="dorzolamide"></drugfyi-drug>